{
    "clinical_study": {
        "@rank": "131295", 
        "arm_group": {
            "arm_group_label": "Itraconazole ointment", 
            "arm_group_type": "Experimental", 
            "description": "Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days."
        }, 
        "brief_summary": {
            "textblock": "This research is being done to study the molecular effects of topically applied itraconazole\n      ointment on the growth of basal cell carcinomas."
        }, 
        "brief_title": "Topical Itraconazole in the Treatment of Basal Cell Carcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Basal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Basal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Basal cell carcinoma is the most common type of skin cancer in Caucasians worldwide.\n      Although rarely metastatic, it can be locally destructive causing disfigurement and pain.\n      Current therapies include surgical removal, local destruction, radiotherapy and others.\n\n      Advances in understanding the molecular basis behind BCCs indicate that mutations in the\n      hedgehog signaling pathway can lead to the development of many sporadically occurring BCCs.\n      An oral drug that targets the hedgehog signaling pathway has been shown to be effective in\n      treating patients with metastatic and inoperable BCCs. There is evidence that itraconazole,\n      a commonly prescribed antifungal medication may also affect this pathway.  It is not known\n      whether itraconazole ointment applied topically can affect the growth of BCCs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants must be over the age of 18 years\n\n          -  Male\n\n          -  Women who do not have child-bearing potential (history of hysterectomy,\n             post-menopausal)\n\n          -  Have a biopsy confirmed BCC that measures at least 6mm in size at the time of the\n             initial evaluation (visit #1);\n\n          -  Participant must be willing and comply with the requirements of the protocol;\n\n          -  Participant must have the ability to understand and communicate with the\n             investigator;\n\n          -  Participant must provide informed consent.\n\n        Exclusion Criteria:\n\n          -  Subject with significant congestive heart failure (CHF) or history of CHF, chronic\n             renal failure, hepatic failure, neuropathy\n\n          -  Subject with current skin diseases that the investigator feels is not safe for study\n             participation including but not limited to severe atopic dermatitis, cutaneous T-cell\n             lymphoma, erythroderma;\n\n          -  Subjects on systemic medications known to affect the Hedgehog pathway (see Appendix\n             I)\n\n          -  Subjects on cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine,\n             dofetilide, triazolam, methadone, levacetylmethadol (levomethadyl), lovastatin,\n             simvastatin, dihydroergotamine, ergometrine (ergonovine), ergotamine and\n             methylergometrine (methylergonovine), cisapride, pimozide, methadone,\n             levacetylmethadol (levomethadyl), quinidine\n\n          -  Subjects with history of hypersensitivity to azoles\n\n          -  Subjects with Gorlin syndrome\n\n          -  Subjects on chronic immunosuppression, or who have a history of compromised immune\n             function (e.g. history of or current malignancy other than BCC/squamous cell skin\n             cancers)\n\n          -  Subjects who do not speak English or have difficulty hearing or are otherwise\n             impaired for providing informed consent and communicating with the investigator;\n\n          -  Subjects with a history of keloids or excessive scarring;\n\n          -  Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum\n\n          -  Women of child-bearing age/potential and/or able to conceive"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120677", 
            "org_study_id": "NA_00077461"
        }, 
        "intervention": {
            "arm_group_label": "Itraconazole ointment", 
            "description": "Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).", 
            "intervention_name": "Itraconazole", 
            "intervention_type": "Drug", 
            "other_name": "Sporanox"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "skin cancer", 
            "basal cell carcinoma"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "ctrep@jhmi.edu", 
                "last_name": "Timothy S Wang, MD", 
                "phone": "410-502-7546"
            }, 
            "contact_backup": {
                "email": "sleung7@jhu.edu", 
                "last_name": "Sherry G Leung", 
                "phone": "410-502-7547"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "Johns Hopkins School of Medicine, Department of Dermatology"
            }, 
            "investigator": {
                "last_name": "Yevgeniy Balagula, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study Investigating Antitumorigenic Potential of Topical Itraconazole in the Treatment of Basal Cell Carcinoma", 
        "overall_contact": {
            "email": "ctrep@jhmi.edu", 
            "last_name": "Timothy S Wang, MD", 
            "phone": "410-502-7546"
        }, 
        "overall_contact_backup": {
            "email": "hopkinsctrep@gmail.com", 
            "last_name": "Yevgeniy Balagula, MD", 
            "phone": "410-502-7547"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Timothy S Wang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will report the proportion of patients by treatment cohort and overall that had a significant downregulation in GLI.", 
            "measure": "Downregulation in Gli expression", 
            "safety_issue": "No", 
            "time_frame": "Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120677"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Timothy Wang, MD", 
            "investigator_title": "Associate Professor, Department of Dermatology, Johns Hopkins School of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Data on adverse events will be collected and reported by treatment cohort and overall.", 
            "measure": "Incidence, timing, and severity of treatment adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "45 days"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}